A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.

ABSTRACT: Antitoxins are needed that can be produced economically with improved safety and shelf life compared to conventional antisera-based therapeutics. Here we report a practical strategy for development of simple antitoxin therapeutics with substantial advantages over currently available treatments. The therapeutic strategy employs a single recombinant 'targeting agent' that binds a toxin at two unique sites and a 'clearing Ab' that binds two epitopes present on each targeting agent. Co-administration of the targeting agent and the clearing Ab results in decoration of the toxin with up to four Abs to promote accelerated clearance. The therapeutic strategy was applied to two Botulinum neurotoxin (BoNT) serotypes and protected mice from lethality in two different intoxication models with an effic

SUBMITTER: Mukherjee J 

PROVIDER: S-EPMC3253120 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature